/cloudfront-us-east-2.images.arcpublishing.com/reuters/PTVCMF2AJJO4LDRRYLRESNVVZA.jpg)
New Chinese antiviral pill yields promising results in recent trials amid China's COVID-19 surge
ChannelnewsasiaDec 30, 2022Dec 30, 2022
Facts
- In a "phase 3" trial conducted in China, a new antiviral pill for the treatment of COVID was found to be as effective as Paxlovid against mild to moderate infection in people determined to be at high risk of severe disease.[1]
- According to a study published in the New England Journal of Medicine on Wednesday, patients who took the pill, known as "VV116," recovered on average one day faster (for a total of four days) when compared to those who took Paxlovid. The researchers also found a lower incidence of adverse effects with the VV116 group compared to the Paxlovid group.[2]
- The efficacy of VV116 in reducing severe symptoms, hospitalization, or death among high-risk, unvaccinated individuals has not yet been determined.[2]
- A standard "phase 3" drug trial typically includes as many as 3K people, though the Paxlovid late-stage trial had 2.2K participants. The VV116 trial was significantly less, with only 380 people taking the medication for five days with a similarly sized group taking Paxlovid instead.[3]
Spin
Narrative B
While VV116 may seem like a promising alternative to Paxlovid, it has not been studied enough. The clinical trials involved too small of a control group, and the results were not clear enough for many authorities and regulators to want to approve or manufacture the drug. It's too early to tell if the new treatment will be able to help China's roiling COVID surge.
